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INTRODUCTION {#ajmga37189-sec-0002}
============

De novo mutations are an important cause of moderate and severe intellectual disability (ID). Heterozygous, de novo loss‐of‐function mutations in *SYNGAP1* have been described in 26 individuals to date \[Hamdan et al., [2009](#ajmga37189-bib-0009){ref-type="ref"}, [2011a](#ajmga37189-bib-0007){ref-type="ref"}, [b](#ajmga37189-bib-0008){ref-type="ref"}; Krepischi et al., [2010](#ajmga37189-bib-0012){ref-type="ref"}; Pinto et al., [2010](#ajmga37189-bib-0015){ref-type="ref"}; Vissers et al., [2010](#ajmga37189-bib-0019){ref-type="ref"}; Zollino et al., [2011](#ajmga37189-bib-0022){ref-type="ref"}; de Ligt et al., [2012](#ajmga37189-bib-0005){ref-type="ref"}; Rauch et al., [2012](#ajmga37189-bib-0017){ref-type="ref"}; Berryer et al., [2013](#ajmga37189-bib-0001){ref-type="ref"}; Carvill et al., [2013](#ajmga37189-bib-0002){ref-type="ref"}; Writzl and Knegt, [2013](#ajmga37189-bib-0021){ref-type="ref"}; Redin et al., [2014](#ajmga37189-bib-0018){ref-type="ref"}\]. *SYNGAP1* encodes Ras/Rap GTPase‐activating protein SynGAP, which is a major component of the post‐synaptic density that regulates synaptic plasticity and ERK/MAPK signaling probably via N‐methyl‐d‐aspartate (NMDA) receptor activation \[Komiyama et al., [2002](#ajmga37189-bib-0011){ref-type="ref"}; Muhia et al., [2010](#ajmga37189-bib-0013){ref-type="ref"}\]. *SYNGAP1* \[603384\] has been coded in Online Mendelian Inheritance in Man (OMIM^®^) as causing mental retardation, autosomal dominant 5 \[612621\].

In 2009, Hamdan et al. first reported the sequencing of *SYNGAP1* in 94 apparently nonsyndromic individuals with intellectual disability; they found de novo mutations in three, thus first‐describing this gene as a cause of nonsyndromic intellectual disability (ID) in humans \[Hamdan et al., [2009](#ajmga37189-bib-0009){ref-type="ref"}\]. This group subsequently published eight further affected individuals through re‐sequencing predominantly ID cohorts enriched for epilepsy \[[2011a](#ajmga37189-bib-0007){ref-type="ref"}, [b](#ajmga37189-bib-0008){ref-type="ref"}; Berryer et al., [2013](#ajmga37189-bib-0001){ref-type="ref"}\]. Carvill et al. performed massively parallel sequencing in 500 individuals with epileptic encephalopathy and identified four patients with de novo *SYNGAP1* mutations \[Carvill et al., [2013](#ajmga37189-bib-0002){ref-type="ref"}\]. Further patients have been described as part of large next generation sequencing studies of individuals with ID \[Vissers et al., [2010](#ajmga37189-bib-0019){ref-type="ref"}; de Ligt et al., [2012](#ajmga37189-bib-0005){ref-type="ref"}; Rauch et al., [2012](#ajmga37189-bib-0017){ref-type="ref"}; Redin et al., [2014](#ajmga37189-bib-0018){ref-type="ref"}\].

In addition, there have been four individuals with genomic deletions of 6p23.1 involving *SYNGAP1*, and one with a de novo apparently balanced reciprocal translocation in which one of the breakpoints disrupts *SYNGAP1* \[Krepischi et al., [2010](#ajmga37189-bib-0012){ref-type="ref"}; Pinto et al., [2010](#ajmga37189-bib-0015){ref-type="ref"}; Klitten et al., [2011](#ajmga37189-bib-0010){ref-type="ref"}; Zollino et al., [2011](#ajmga37189-bib-0022){ref-type="ref"}; Writzl and Knegt, [2013](#ajmga37189-bib-0021){ref-type="ref"}\]. Thus the 26 individuals reported to date consist of 21 intragenic mutations, four whole gene deletions, and one translocation. To date, facial images have only been published in six individuals: three in the seminal Hamdan et al. paper, plus three single patients in subsequent papers \[Hamdan et al., [2009](#ajmga37189-bib-0009){ref-type="ref"}; Zollino et al., [2011](#ajmga37189-bib-0022){ref-type="ref"}; Rauch et al., [2012](#ajmga37189-bib-0017){ref-type="ref"}; Writzl and Knegt, [2013](#ajmga37189-bib-0021){ref-type="ref"}\].

Here, we present molecular and clinical information on 10 previously unreported individuals with de novo mutations in *SYNGAP1*, most of whom were diagnosed using trio exome sequencing of individuals with undiagnosed developmental disorders. The relatively consistent pattern of clinical features and behavioral anomalies observed in these individuals and in previously reported individuals suggests that there is an emerging *SYNGAP1*‐associated syndrome.

METHODS {#ajmga37189-sec-0003}
=======

Patient Ascertainment {#ajmga37189-sec-0004}
---------------------

Seven of the 10 affected individuals were recruited via UK NHS Regional Genetics Services to the Deciphering Developmental Disorders (DDD) study ([www.ddduk.org](http://www.ddduk.org)). The eighth individual (7; Table [I](#ajmga37189-tbl-0001){ref-type="table-wrap"}) was identified as part of routine investigation of ID via a UK NHS paediatric genetics clinic. These eight individuals were seen by the same Paediatric Geneticist (MJP) in addition to the referring Clinical Geneticists. The ninth and tenth individuals are monozygotic twins who were referred for genetic evaluation to the local multi‐disciplinary clinic for children with intellectual disability. See Table [I](#ajmga37189-tbl-0001){ref-type="table-wrap"} for a summary of the clinical and molecular findings. The Supporting Information online provides additional clinical details.

###### 

Clinical Features of Ten Previously‐Unreported Patients With *SYNGAP1* Haploinsufficiency Reported Herein

  Category/Individual                            1                                                               2                                                                          3                                                                   4                                                                                  5                                                                 6                                                        7                                                          8                                                   9                                                                      10
  ---------------------------------------------- --------------------------------------------------------------- -------------------------------------------------------------------------- ------------------------------------------------------------------- ---------------------------------------------------------------------------------- ----------------------------------------------------------------- -------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------- ---------------------------------------------------------------------- ----------------------------------------------------------------------
  DECIPHER ID                                    259041                                                          259840                                                                     258913                                                              264135                                                                             259214                                                            259606                                                   258536                                                     258536                                              LEM300469                                                              LEM300468
  Mutation details                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Genomic coordninates (chr6; hg19)              chr6 g.33406569 CTGTATG\>CTG                                    chr6 g.33400583G\>A                                                        chr6 g.33411111C\>T                                                 chr6 g.33411093C\>T                                                                chr6 g.33400498 AAACGAACGAA\> AAACGAA                             chr6 g.33411102CT\>C                                     deletion chr6:33201710‐ 33595089                           chr6 g.33411606C\>T                                 chr6 g.33405662T\>C                                                    
  VEP prediction                                 Transcript; ENST00000418600 frameshift_variant p.LYE517‐519LX   Transcript; ENST00000418600 missense_variant p.R170Q                       Transcript; ENST00000418600 stop_gained p.Q928\*                    Transcript; ENST00000418600 stop_gained p.R922\*                                   Transcript: ENST00000418600 frameshift_variant p.KRTK142‐145KRX   Transcript; ENST00000418600 frameshift_variant p.L925X   multi‐gene deletion; SYNGAP1 plus 18 others                Transcript; ENST00000449372 stop gained p.Q1079\*   Transcript; NM_006772.2 missense_variant p.Leu327Pro                   
  Inheritance                                    de novo                                                         de novo                                                                    de novo                                                             de novo                                                                            de novo                                                           de novo                                                  de novo                                                    de novo                                             de novo                                                                de novo
  Age (years)                                    7                                                               8                                                                          7                                                                   3                                                                                  8                                                                 12                                                       5                                                          8                                                   14                                                                     14
  Sex                                            Female                                                          Female                                                                     Female                                                              Female                                                                             Male                                                              Female                                                   Female                                                     Female                                              Male                                                                   Male
  Prenatal growth                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Gestation (weeks)                              40                                                              30                                                                         40                                                                  41                                                                                 40                                                                40                                                       41                                                         40                                                  35                                                                     35
  Birth weight (g) \[z score\]                   4100 \[1.67\]                                                   1360 \[0.07\]                                                              3090 \[−0.68\]                                                      3600 \[0.2\]                                                                       3460 \[0.21\]                                                     3180 \[−0.46\]                                           3190 \[−0.78\]                                             3650 \[0.65\]                                       2465 \[−0.11\]                                                         2460 \[−0.12\]
  Head circumference at birth (cm) \[z score\]   −                                                               −                                                                          −                                                                   −                                                                                  −                                                                 −                                                        −                                                          −                                                   32 \[−1\]                                                              31.5 \[−1.3\]
  NICU admission                                 No                                                              4 weeks                                                                    No                                                                  No                                                                                 No                                                                No                                                       No                                                         No                                                  −                                                                      −
  Postnatal growth                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Age when measured (yrs)                        7.1                                                             8.0                                                                        7.1                                                                 3.1                                                                                8.1                                                               12.1                                                     5.1                                                        8.1                                                 8 y 3 mo                                                               8 y 3 mo
  Height (cm) \[z score\]                        117.5 \[−0.82\]                                                 132 \[0.85\]                                                               116.4 \[−1.03\]                                                     93.5 \[−.0.45\]                                                                    120 \[−1.5\]                                                      131.6 \[−2.6\]                                           103 \[−1.4\]                                               132.5 \[0.85\]                                      119 \[−1.8\]                                                           110 \[−3.4\]
  Weight (kg) \[z score\]                        24.8 \[0.42\]                                                   37.7 \[2.0\]                                                               22.7 \[−0.15\]                                                      11.5 \[−1.98\]                                                                     23.5 \[−0.69\]                                                    29.4 \[−1.86\]                                           17.2 \[−0.55\]                                             30.5 \[0.89\]                                       23 \[−0.98\]                                                           16 \[−4.4\]
  Head circumference (cm) \[z score\]            50.7 \[−1.6\]                                                   54 \[0.81\]                                                                49.5 \[−2.6\]                                                       47.4 \[−2.5\]                                                                      52.2 \[−1.1\]                                                     52 \[−1.83\]                                             48.2 \[−2.9\]                                              53 \[−0.03\]                                        52.4 \[−0.98\]                                                         52 \[−1.2\]
  Facial dysmorphology                           Long nose; broad ‐sal bridge; full lower lip                    Broad ‐sal bridge; full lower lip                                          Long nose; broad ‐sal bridge; small ears; full lower lip            Long nose; broad ‐sal bridge; full lower lip                                       Triangular face; protuberant ears                                 Long nose; full lower lip                                Long nose; broad ‐sal bridge; small ears; full lower lip   Broad ‐sal bridge; full lower lip; ptosis           Deep‐set eyes, high ‐sal bridge; long columella; high‐arched palate    Deep‐set eyes, high ‐sal bridge; long columella; high‐arched palate
  Neurology, behavior, development                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Intellectual disability                        Moderate                                                        Moderate                                                                   Moderate                                                            Moderate                                                                           Moderate                                                          Moderate                                                 Moderate                                                   Moderate                                            Severe                                                                 Severe
  Sat unaided (months)                           20                                                              7                                                                          12                                                                  24                                                                                 15                                                                Uncertain                                                7                                                          12                                                  24--36                                                                 24--36
  Walked unaided (months)                        24                                                              36                                                                         60                                                                  NYA                                                                                17                                                                24                                                       19                                                         30                                                  \>60                                                                   \>60
  Speech                                         40--50 single words; occasional two‐word sentences              Several single words; signs                                                Occasional single word                                              NYA                                                                                ∼200 single words                                                 20 single words; Points; Signs                           Two‐word sentences                                         Four‐word sentences; echolalia                      NYA                                                                    NYA
  Behavior                                       Aggressive (self & others); routine‐orientated                  Aggressive (others); routine‐orientated; obsessions                        Aggressive (self & others); routine‐orientated; hand stereotypies   Aggressive (self & others); obsessions (water)                                     Aggressive (self); obsessions (doors)                             Aggressive (others); hand flapping when excited          Aggressive (self & others); obsessions (water)             Autistic spectrum disorder                          Routine‐orientated, fasci‐tion with water; laughter outbursts          Routine‐orientated, fasci‐tion with water; laughter outbursts
  Autism                                         −                                                               Yes                                                                        No                                                                  Yes                                                                                Yes                                                               Yes                                                      −                                                          No                                                  Yes                                                                    Yes
  Sleep disturbance                              Yes                                                             Yes                                                                        Yes                                                                 Yes                                                                                Yes                                                               Yes                                                      Yes                                                        Yes (not severe)                                    Yes                                                                    Yes
  Hypotonia                                      No                                                              Yes                                                                        Yes                                                                 Yes                                                                                Yes                                                               No                                                       Yes                                                        Yes                                                 Yes                                                                    Yes
  Seizures                                       No                                                              Yes                                                                        Yes                                                                 Yes                                                                                No                                                                Yes                                                      No                                                         Yes                                                 Yes                                                                    Yes
  Seizure age‐of‐onset                           −                                                               6 y                                                                        2 y                                                                 2 y                                                                                −                                                                 3 y                                                      −                                                          5 y                                                 13 m                                                                   13 m
  Seizure type                                   −                                                               Myoclonic; absences                                                        Myoclonic; absences; drop attacks                                   Absences; drop attacks                                                             −                                                                 Head drops & blinking, visually triggered by patterns    −                                                          Absences (possible); drop attacks                   Febrile; absences; drop attacks; occasional tonic‐clonic & myoclonic   Febrile; absences; drop attacks; occasional tonic‐clonic & myoclonic
  Gait                                           Unsteady gait                                                   Wide‐based gait                                                            Wide‐based gait                                                     −                                                                                  −                                                                 Wide‐based gait                                          Unsteady gait                                              −                                                   Ataxic                                                                 Ataxic
  Brain MRI                                      ND                                                              Normal                                                                     Normal                                                              Normal                                                                             Normal                                                            Normal                                                   ND                                                         ND                                                  Normal                                                                 Normal
  Skeletal issues                                No                                                              Hip dysplasia (unilateral, requiring osteotomy); 5th finger clinodactyly   Pes planus                                                          Pectus excavatum; kyphosis; hip dysplasia (unilateral, requiring open reduction)   Pes planus                                                        No                                                       No                                                         Lordosis                                            Kyphoscoliosis                                                         Kyphoscoliosis
  Other issues                                   Gastro‐esophageal reflux                                        Constipation; café‐au‐lait patch (arm)                                     Constipation; unilateral divergent strabismus                       Constipation; gastrostomy planned; hirsutism                                       Café‐au‐lait patch (intercostal)                                  Constipation; hirsutism                                  Hirsutism; unilateral divergent strabismus                 Constipation; strabismus (repaired)                 Progressive lower limb spasticity                                      Progressive lower limb spasticity; gastrostomy

Key: NYA, not yet achieved; ND, not done.

© 2015 Wiley Periodicals, Inc.

Mutation Analysis {#ajmga37189-sec-0005}
-----------------

For the seven individuals identified via the DDD study, trio‐based exome sequencing was performed on the affected individual and their parents, as previously described \[Wright et al., [2014](#ajmga37189-bib-0020){ref-type="ref"}\]. Each affected individual has also had a high‐resolution analysis for copy number abnormalities using array‐based comparative genomic hybridization (aCGH). Putative de novo mutations were identified from exome data using DeNovoGear software \[Ramu et al., [2013](#ajmga37189-bib-0016){ref-type="ref"}\] and were validated using targeted Sanger sequencing.

The eighth individual (7; Table [I](#ajmga37189-tbl-0001){ref-type="table-wrap"}) was identified as having a ∼0.39Mb deletion of 6p21.32p21.31, via a service ISCA 8 × 60K BlueGnome Array. The ninth and tenth individuals are monozygous twins from Belgium, who were identified through a local multi‐gene panel and were validated using targeted Sanger sequencing.

RESULTS {#ajmga37189-sec-0006}
=======

*SYNGAP1* Mutations {#ajmga37189-sec-0007}
-------------------

The validated de novo mutations are detailed in Table [I](#ajmga37189-tbl-0001){ref-type="table-wrap"}. There were 10 individuals, but two are monozygotic twins, so we describe eight mutations and one deletion. Three individuals had nonsense mutations; three had frameshift mutations resulting in early stop codons. One individual (2; Table [I](#ajmga37189-tbl-0001){ref-type="table-wrap"}) had a missense mutation c.509G\>A (ENST00000418600); p.Arg170Gln (ENSP00000403636.2). On SIFT analysis; this was labeled "Deleterious" with a score of 0.01 and on PolyPhen analysis "Possibly damaging" with a score of 0.529. This mutated residue lies within the PH domain (Prosite PS50003) of SynGAP. The monozygotic twins (9 and 10; Table [I](#ajmga37189-tbl-0001){ref-type="table-wrap"}) had a missense mutation c.1081T\>C (ENST00000418600); p.Leu327Pro (ENSP00000403636). The SIFT score is 0, "Deleterious", and the PolyPhen is 0.983, "Probably Damaging". This mutation lies within the C2 domain, which is required for RapGAP activity. One individual (7; Table [I](#ajmga37189-tbl-0001){ref-type="table-wrap"}) had a 0.39 Mb genomic deletion, which encompassed the entire *SYNGAP1* gene and 18 other genes.

Growth {#ajmga37189-sec-0008}
------

Birth weight was normal (z score between −2 and 2) for all of the affected individuals. Postnatal growth was normal in five individuals (1, 2, 5, 8 and 9; Table [I](#ajmga37189-tbl-0001){ref-type="table-wrap"}). Three of 10 had mild microcephaly (z score between −2.5 and −3), with one of these also having weight on a similar centile (4; Table [I](#ajmga37189-tbl-0001){ref-type="table-wrap"}). Two individuals had significant short stature (Patients 6 and 10; Table [I](#ajmga37189-tbl-0001){ref-type="table-wrap"}), one of whom was also significantly underweight (Patient 10; Table [I](#ajmga37189-tbl-0001){ref-type="table-wrap"}).

Development {#ajmga37189-sec-0009}
-----------

Global delay in developmental milestones was present in all patients with an unusual temporal sequence seen in some patients. For example, Patient 5 (Table [I](#ajmga37189-tbl-0001){ref-type="table-wrap"}) did not sit unaided until 15 months, but walked unaided at 17 months. Typically independent walking was achieved in the third year of life with the subsequent gait being wide‐based and unsteady. Language acquisition was highly variable within this group. Expressive language was delayed with most children using a limited vocabulary of single words. None of the affected individuals were toilet‐trained at the time of assessment.

Behavior {#ajmga37189-sec-0010}
--------

Seven of the ten individuals showed general hyperexcitability and aggressive behavior, often directed towards others. A disturbed sleep pattern was reported in all patients, with almost all being treated with, or having had a therapeutic trial of, Melatonin. Anecdotally, families reported a high pain threshold and hyperacusis in some affected individuals.

Neurology {#ajmga37189-sec-0011}
---------

Seven of the 10 individuals had seizures, most commonly complex and generalized, including myoclonic, drop attacks, and absences. Congenital central hypotonia was common. Most of the affected individuals required ankle splints and/or Piedro boots to aid with walking. Seven individuals have had MR imaging of their brains and in each patient this was reported as normal.

Facial Features {#ajmga37189-sec-0012}
---------------

The facial appearance of the ten affected individuals is shown in Figure [1](#ajmga37189-fig-0001){ref-type="fig"}. The most common shared facial characteristics are almond‐shaped palpebral fissures, which slant downwards slightly. All but one had a mildly myopathic appearance. An open‐mouthed appearance, with a relatively full lower lip vermilion was common, as was a low‐hanging columella. 7/10 had relatively long noses (sometimes with under‐development of the ala nasi); 6/10 had relatively long ears with protuberant lobes; 4/10 had relatively deep‐set eyes; and one had a degree of ptosis. There was no obvious difference in facial appearance between the deletion and intragenic mutation patients.

![Faces of individuals with *SYNGAP1* haploinsufficiency. Facial photographs of Patient 1 at 7 years, 3 months (**a**); Patient 2 at 8 years, 2 months (**b**); Patient 3 at 7 years, 9 months (**c**); Patient 4 at 3 years, 2 months (**d**); Patient 5 at 8 years, 4 months (**e**); Patient 6 at 12 years, 10 months (**f**); Patient 7 at 5 years, 7 months (**g**); Patient 8 at 8 years, 7 months (**h**); and Patients 9 and 10 at 8 years, 3 months (**i** and **j**). The most common shared facial characteristics are almond‐shaped palpebral fissures, which slant downwards slightly. With the exception of Patient 5 (**e**), the others have a mildly myopathic appearance, with an open mouth and relatively full lower lip. Patients 1 (**a**), 3 (**c**), 4 (**d**), 6 (**f**), 7 (**g**) and 9 (**i**) and 10 (**j**) have relatively long noses; Patients 2 (**b**), 4 (**d**), 5 (**e**), 6 (**f**), 7 (**g**) and 8 (**h**) have relatively long ears with protuberant lobes. Patients 1 (**a**), 6 (**f**) and 9 (**i**) and 10 (**j**) were thought to have relatively deep‐set eyes and Patient 8 (**h**) has a degree of ptosis. Patient 6 (**f**) has a missing central incisor due to trauma. We do not believe that Patient 7 (**g**), the only deletion patient in this series, differs significantly in appearance from the others.](AJMG-167-2231-g001){#ajmga37189-fig-0001}

Other Features {#ajmga37189-sec-0013}
--------------

Five of the individuals had constipation, requiring medical therapies; three individuals had fine hirsutism, especially noticeable over limbs and spine; two had significant hip dysplasia, requiring surgical management; three had a kyphosis or kyphoscoliosis; and one had a pectus excavatum (Table [I](#ajmga37189-tbl-0001){ref-type="table-wrap"}).

DISCUSSION {#ajmga37189-sec-0014}
==========

*SYNGAP1* was originally reported as causing non‐syndromal intellectual disability \[Hamdan et al., [2009](#ajmga37189-bib-0009){ref-type="ref"}\]. Supplementary Table I summarizes the available clinical data on the 26 individuals who have been reported to date with presumed causative mutations in *SYNGAP1* or deletions or translocations involving this gene \[Hamdan et al., [2009](#ajmga37189-bib-0009){ref-type="ref"}, [2011a](#ajmga37189-bib-0007){ref-type="ref"}, [b](#ajmga37189-bib-0008){ref-type="ref"}; Krepischi et al., [2010](#ajmga37189-bib-0012){ref-type="ref"}; Pinto et al., [2010](#ajmga37189-bib-0015){ref-type="ref"}; Vissers et al., [2010](#ajmga37189-bib-0019){ref-type="ref"}; Cook, [2011](#ajmga37189-bib-0004){ref-type="ref"}; Klitten et al., [2011](#ajmga37189-bib-0010){ref-type="ref"}; Zollino et al., [2011](#ajmga37189-bib-0022){ref-type="ref"}; Clement et al., [2012](#ajmga37189-bib-0003){ref-type="ref"}; de Ligt et al., [2012](#ajmga37189-bib-0005){ref-type="ref"}; Rauch et al., [2012](#ajmga37189-bib-0017){ref-type="ref"}; Berryer et al., [2013](#ajmga37189-bib-0001){ref-type="ref"}; Carvill et al., [2013](#ajmga37189-bib-0002){ref-type="ref"}; Writzl and Knegt, [2013](#ajmga37189-bib-0021){ref-type="ref"}; Dyment et al., [2014](#ajmga37189-bib-0006){ref-type="ref"}; O\'Roak et al., [2014](#ajmga37189-bib-0014){ref-type="ref"}; Redin et al., [2014](#ajmga37189-bib-0018){ref-type="ref"}\]. De novo mutations in this gene are undoubtedly a significant cause of intellectual disability, accounting for 0.62% of all the patients in the DDD Study \[Wright et al., [2014](#ajmga37189-bib-0020){ref-type="ref"}\] and major contributors to other cohorts that have been studied (Supplementary Table II).

The original designation of the phenotype associated with *SYNGAP1* haploinsufficiency as non‐syndromal is understandable given the generally normal antenatal growth parameters and the relative normality of post‐natal growth. In addition, all patients have a moderate‐to‐severe intellectual disability with few structural anomalies reported on brain imaging. The genomic pathology is also remarkably consistent with almost all patients having heterozygous, de novo, loss of function mutations. The associated genetic mechanism is very likely to be haploinsufficiency given the similarity of the intragenic mutations with the whole gene deletions.

Although there is wide variability in the type and severity of the clinical features associated with *SYNGAP1* haploinsufficiency, some aspects of the phenotype show a level of consistency that suggests *SYNGAP1* haploinsufficiency may be associated with a clinically recognizable syndrome. The seizure type and the behavioral phenotype were relatively consistent in our cohort. Myoclonic, absence and drop attack seizures are typical, both in the reported individuals and those presented in this paper. General hyperexcitability, sleep disturbance and aggressive behavior, often directed towards others, are common features in our cohort and are mentioned in some of the previously reported patients. Clearly these distressing behavioral components of the phenotype require further investigation. Facial photographs were not available in most of the previous reports, but in the cohort presented here a subtle but consistent facial appearance is suggested, although further observations will be required to determine if this is in any way discriminative. The pattern of growth may also be helpful in making a clinical diagnosis. Six of 18 reported patients with postnatal head circumferences recorded, and 3/10 of the patients reported here, had measurements of two standard deviations below the mean for their age. A mild postnatal microcephaly is clearly over‐represented in this group.

In our cohort, 8/10 patients had previously been investigated for Angelman syndrome. There are some similarities with this condition, although we believe that they are clinically distinguishable. Nevertheless, we believe that *SYNGAP1* should also be added to the expanding list of differential diagnoses for Angelman syndrome or patients presenting with Angelman‐like features.

CONCLUSION {#ajmga37189-sec-0015}
==========

*SYNGAP1* has previously been described as presenting in a non‐syndromal manner. Mutations in this gene have been found to be a relatively‐common cause of intellectual disability in large‐scale massively parallel sequencing studies, where subjects are usually recruited because a clinical syndromal diagnosis has not previously been made. It is arguable whether the term non‐specific may be more appropriate to many subjects recruited into such studies, who most likely represent a heterogeneous mix of those genuinely non‐syndromal, but also of some syndromes more subtle in their associations and/or dysmorphology. For *SYNGAP1* we consider discriminative features in individuals with moderate‐to‐severe ID to be the characteristic facial features, seizure type and behavioral phenotype (generalized hyper‐excitability, sleep disturbance and a propensity to aggression). It is not yet clear if hypotonia, hip dysplasia, strabismus, wide‐based/unsteady gait, fine hirsutism (limbs and spine), and significant constipation are helpful discriminators. Some patients have microcephaly, but growth parameters are generally within the normal range.

Supporting information
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Additional supporting information may be found in the online version of this article at the publisher\'s web‐site.
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**Supporting Information Table S1**: Summarizes the available clinical data on the 26 individuals who have been previously‐reported with presumed causative mutations in *SYNGAP1*, deletions or translocations involving this gene.
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Click here for additional data file.
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**Supporting Information Table S2**: Summarizes the *SYNGAP1* pick‐up rate in NGS studies in which *SYNGAP1* patients have previously been reported.
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Click here for additional data file.
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